Interviews

Sameera Kumar, MD, highlights the role radiation plays in the treatment of patients with stage 3 non-small cell lung cancer.

Juan Gimenez, MD, discusses the implications of a recent analysis of yttrium-90 (Y-90) glass microsphere radioembolization for interventional radiology.

Additional confirmatory tests for progressive disease are not needed to determine progression among patients with MM after 2 biomarkers have met the criteria of progression at the same time, according to a retrospective study.

In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.

At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.

Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.

Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.

Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.

Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.

Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.